Cancer epigenetics: From mechanism to therapy

Cell

Volumn 150, Issue 1, 2012, Pages 12-27

  Dawson, Mark A ^a,b   Kouzarides, Tony ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 CARBOXYLCYTOSINE; 5 FORMYLCYTOSINE; 5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; AZACITIDINE; CYTOSINE DERIVATIVE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; HISTONE METHYLTRANSFERASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; ROMIDEPSIN; RUXOLITINIB; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADENOSINE DIPHOSPHATE RIBOSYLATION; BUTYRYLATION; CANCER EPIGENETICS; CANCER GENETICS; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME TRANSLOCATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CPG ISLAND; CROTONYLATION; DEIMINATION; DNA METHYLATION; DNA MODIFICATION; DNA TEMPLATE; DRUG TARGETING; EPIGENETICS; FORMYLATION; GENE MUTATION; GENOME; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HISTONE UBIQUITINATION; HUMAN; HYDROXYLATION; ISOMERIZATION; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; NUCLEOSOME; O GLCNACYLATION; OXIDATION; PRIORITY JOURNAL; PROPIONYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; QUALITY OF LIFE; REVIEW; SUMOYLATION;

EID: 84863621527     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2012.06.013     Document Type: Review

References (116)

1. V.G. Allfrey, R. Faulkner, and A.E. Mirsky Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis Proc. Natl. Acad. Sci. USA 51 1964 786 794
2. C.D. Allis, T. Jenuwein, and D. Reinberg Epigenetics 2007 Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY
3. P.P. Amaral, M.E. Dinger, T.R. Mercer, and J.S. Mattick The eukaryotic genome as an RNA machine Science 319 2008 1787 1789 (Pubitemid 351451554)
4. N. Avvakumov, and J. Côté The MYST family of histone acetyltransferases and their intimate links to cancer Oncogene 26 2007 5395 5407 (Pubitemid 47255922)
5. S.H. Baek When signaling kinases meet histones and histone modifiers in the nucleus Mol. Cell 42 2011 274 284
6. A.J. Bannister, and T. Kouzarides The CBP co-activator is a histone acetyltransferase Nature 384 1996 641 643 (Pubitemid 27021517)
7. M. Bantscheff, C. Hopf, M.M. Savitski, A. Dittmann, P. Grandi, A.-M. Michon, J. Schlegl, Y. Abraham, I. Becher, and G. Bergamini Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes Nat. Biotechnol. 29 2011 255 265
8. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, S. Kim, C.J. Wilson, J. Lehár, G.V. Kryukov, and D. Sonkin The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
9. A. Barski, S. Cuddapah, K. Cui, T.-Y. Roh, D.E. Schones, Z. Wang, G. Wei, I. Chepelev, and K. Zhao High-resolution profiling of histone methylations in the human genome Cell 129 2007 823 837 (Pubitemid 46802390)
10. T. Bartke, M. Vermeulen, B. Xhemalce, S.C. Robson, M. Mann, and T. Kouzarides Nucleosome-interacting proteins regulated by DNA and histone methylation Cell 143 2010 470 484
11. S.B. Baylin, and P.A. Jones A decade of exploring the cancer epigenome - biological and translational implications Nat. Rev. Cancer 11 2011 726 734
12. O.R. Bereshchenko, W. Gu, and R. Dalla-Favera Acetylation inactivates the transcriptional repressor BCL6 Nat. Genet. 32 2002 606 613 (Pubitemid 35435172)
13. S.L. Berger, T. Kouzarides, R. Shiekhattar, and A. Shilatifard An operational definition of epigenetics Genes Dev. 23 2009 781 783
14. B.P. Berman, D.J. Weisenberger, J.F. Aman, T. Hinoue, Z. Ramjan, Y. Liu, H. Noushmehr, C.P. Lange, C.M. van Dijk, and R.A. Tollenaar Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains Nat. Genet. 44 2012 40 46
15. B.E. Bernstein, T.S. Mikkelsen, X. Xie, M. Kamal, D.J. Huebert, J. Cuff, B. Fry, A. Meissner, M. Wernig, and K. Plath A bivalent chromatin structure marks key developmental genes in embryonic stem cells Cell 125 2006 315 326
16. D. Bungard, B.J. Fuerth, P.Y. Zeng, B. Faubert, N.L. Maas, B. Viollet, D. Carling, C.B. Thompson, R.G. Jones, and S.L. Berger Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation Science 329 2010 1201 1205
17. M.A. Chapman, M.S. Lawrence, J.J. Keats, K. Cibulskis, C. Sougnez, A.C. Schinzel, C.L. Harview, J.P. Brunet, G.J. Ahmann, and M. Adli Initial genome sequencing and analysis of multiple myeloma Nature 471 2011 467 472
18. C. Choudhary, C. Kumar, F. Gnad, M.L. Nielsen, M. Rehman, T.C. Walther, J.V. Olsen, and M. Mann Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 325 2009 834 840
19. C.W. Chung, and J. Witherington Progress in the discovery of small-molecule inhibitors of bromodomain - histone interactions J. Biomol. Screen. 16 2011 1170 1185
20. L. Cimmino, O. Abdel-Wahab, R.L. Levine, and I. Aifantis TET family proteins and their role in stem cell differentiation and transformation Cell Stem Cell 9 2011 193 204
21. P.A. Cole Chemical probes for histone-modifying enzymes Nat. Chem. Biol. 4 2008 590 597
22. A.H. Coles, and S.N. Jones The ING gene family in the regulation of cell growth and tumorigenesis J. Cell. Physiol. 218 2009 45 57
23. S.R. Daigle, E.J. Olhava, C.A. Therkelsen, C.R. Majer, C.J. Sneeringer, J. Song, L.D. Johnston, M.P. Scott, J.J. Smith, and Y. Xiao Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor Cancer Cell 20 2011 53 65
24. M.A. Dawson, A.J. Bannister, B. Göttgens, S.D. Foster, T. Bartke, A.R. Green, and T. Kouzarides JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin Nature 461 2009 819 822
25. M.A. Dawson, R.K. Prinjha, A. Dittmann, G. Giotopoulos, M. Bantscheff, W.I. Chan, S.C. Robson, C.W. Chung, C. Hopf, and M.M. Savitski Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 478 2011 529 533
26. E. de Wit, and W. de Laat A decade of 3C technologies: insights into nuclear organization Genes Dev. 26 2012 11 24
27. K. Deguchi, P.M. Ayton, M. Carapeti, J.L. Kutok, C.S. Snyder, I.R. Williams, N.C.P. Cross, C.K. Glass, M.L. Cleary, and D.G. Gilliland MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP Cancer Cell 3 2003 259 271 (Pubitemid 37443881)
28. F. Delhommeau, S. Dupont, V. Della Valle, C. James, S. Trannoy, A. Massé, O. Kosmider, J.P. Le Couedic, F. Robert, and A. Alberdi Mutation in TET2 in myeloid cancers N. Engl. J. Med. 360 2009 2289 2301
29. J.E. Delmore, G.C. Issa, M.E. Lemieux, P.B. Rahl, J. Shi, H.M. Jacobs, E. Kastritis, T. Gilpatrick, R.M. Paranal, and J. Qi BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 146 2011 904 917
30. G.K. Dialynas, M.W. Vitalini, and L.L. Wallrath Linking Heterochromatin Protein 1 (HP1) to cancer progression Mutat. Res. 647 2008 13 20
31. H. Easwaran, S.E. Johnstone, L. Van Neste, J. Ohm, T. Mosbruger, Q. Wang, M.J. Aryee, P. Joyce, N. Ahuja, and D. Weisenberger A DNA hypermethylation module for the stem/progenitor cell signature of cancer Genome Res. 22 2012 837 849
32. T. Ernst, A.J. Chase, J. Score, C.E. Hidalgo-Curtis, C. Bryant, A.V. Jones, K. Waghorn, K. Zoi, F.M. Ross, and A. Reiter Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Nat. Genet. 42 2010 722 726
33. P.J. Farnham Insights from genomic profiling of transcription factors Nat. Rev. Genet. 10 2009 605 616
34. M. Federico, and L. Bagella Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors J. Biomed. Biotechnol. 2011 2011 475641
35. A.P. Feinberg, and B. Tycko The history of cancer epigenetics Nat. Rev. Cancer 4 2004 143 153 (Pubitemid 38198742)
36. P. Fenaux, G.J. Mufti, E. Hellstrom-Lindberg, V. Santini, C. Finelli, A. Giagounidis, R. Schoch, N. Gattermann, G. Sanz, A. List International Vidaza High-Risk MDS Survival Study Group Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol. 10 2009 223 232
37. P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W.B. Smith, O. Fedorov, E.M. Morse, T. Keates, T.T. Hickman, and I. Felletar Selective inhibition of BET bromodomains Nature 468 2010 1067 1073
38. S.A. Forbes, N. Bindal, S. Bamford, C. Cole, C.Y. Kok, D. Beare, M. Jia, R. Shepherd, K. Leung, and A. Menzies COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic Acids Res. 39 Database issue 2011 D945 D950
39. M.F. Fraga, E. Ballestar, A. Villar-Garea, M. Boix-Chornet, J. Espada, G. Schotta, T. Bonaldi, C. Haydon, S. Ropero, and K. Petrie Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer Nat. Genet. 37 2005 391 400
40. M.J. Garnett, E.J. Edelman, S.J. Heidorn, C.D. Greenman, A. Dastur, K.W. Lau, P. Greninger, I.R. Thompson, X. Luo, and J. Soares Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 483 2012 570 575
41. S.D. Gore New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome Hematology (Am. Soc. Hematol. Educ. Program) 2011 2011 550 555
42. Y. Gui, G. Guo, Y. Huang, X. Hu, A. Tang, S. Gao, R. Wu, C. Chen, X. Li, and L. Zhou Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder Nat. Genet. 43 2011 875 878
43. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
44. N.D. Heintzman, R.K. Stuart, G. Hon, Y. Fu, C.W. Ching, R.D. Hawkins, L.O. Barrera, S. Van Calcar, C. Qu, and K.A. Ching Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome Nat. Genet. 39 2007 311 318 (Pubitemid 46328487)
45. N.D. Heintzman, G.C. Hon, R.D. Hawkins, P. Kheradpour, A. Stark, L.F. Harp, Z. Ye, L.K. Lee, R.K. Stuart, and C.W. Ching Histone modifications at human enhancers reflect global cell-type-specific gene expression Nature 459 2009 108 112
46. B.J. Huntly, H. Shigematsu, K. Deguchi, B.H. Lee, S. Mizuno, N. Duclos, R. Rowan, S. Amaral, D. Curley, and I.R. Williams MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors Cancer Cell 6 2004 587 596 (Pubitemid 40017702)
47. N.G. Iyer, H. Ozdag, and C. Caldas p300/CBP and cancer Oncogene 23 2004 4225 4231 (Pubitemid 38758588)
48. Y. Jiao, C. Shi, B.H. Edil, R.F. de Wilde, D.S. Klimstra, A. Maitra, R.D. Schulick, L.H. Tang, C.L. Wolfgang, and M.A. Choti DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331 2011 1199 1203
49. R.W. Johnstone, and J.D. Licht Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4 2003 13 18 (Pubitemid 36904157)
50. S. Jones, T.L. Wang, IeM. Shih, T.L. Mao, K. Nakayama, R. Roden, R. Glas, D. Slamon, L.A. Diaz Jr., and B. Vogelstein Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma Science 330 2010 228 231
51. R.J. Klose, and A.P. Bird Genomic DNA methylation: the mark and its mediators Trends Biochem. Sci. 31 2006 89 97 (Pubitemid 43221841)
52. R. Kogo, T. Shimamura, K. Mimori, K. Kawahara, S. Imoto, T. Sudo, F. Tanaka, K. Shibata, A. Suzuki, and S. Komune Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers Cancer Res. 71 2011 6320 6326
53. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705 (Pubitemid 46273577)
54. S. Kriaucionis, and N. Heintz The nuclear DNA base 5- hydroxymethylcytosine is present in Purkinje neurons and the brain Science 324 2009 929 930
55. A.V. Krivtsov, and S.A. Armstrong MLL translocations, histone modifications and leukaemia stem-cell development Nat. Rev. Cancer 7 2007 823 833 (Pubitemid 350006257)
56. P.W. Laird Principles and challenges of genomewide DNA methylation analysis Nat. Rev. Genet. 11 2010 191 203
57. S.M. Langemeijer, R.P. Kuiper, M. Berends, R. Knops, M.G. Aslanyan, M. Massop, E. Stevens-Linders, P. van Hoogen, A.G. van Kessel, and R.A. Raymakers Acquired mutations in TET2 are common in myelodysplastic syndromes Nat. Genet. 41 2009 838 842
58. J.S. Lee, E. Smith, and A. Shilatifard The language of histone crosstalk Cell 142 2010 682 685
59. T.J. Ley, L. Ding, M.J. Walter, M.D. McLellan, T. Lamprecht, D.E. Larson, C. Kandoth, J.E. Payton, J. Baty, and J. Welch DNMT3A mutations in acute myeloid leukemia N. Engl. J. Med. 363 2010 2424 2433
60. E. Li, T.H. Bestor, and R. Jaenisch Targeted mutation of the DNA methyltransferase gene results in embryonic lethality Cell 69 1992 915 926
61. D.Q. Li, S.B. Pakala, S.S. Nair, J. Eswaran, and R. Kumar Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer Cancer Res. 72 2012 387 394
62. R.B. Lorsbach, J. Moore, S. Mathew, S.C. Raimondi, S.T. Mukatira, and J.R. Downing TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23) Leukemia 17 2003 637 641 (Pubitemid 36395661)
63. R. Margueron, and D. Reinberg The Polycomb complex PRC2 and its mark in life Nature 469 2011 343 349
64. J.A. Mertz, A.R. Conery, B.M. Bryant, P. Sandy, S. Balasubramanian, D.A. Mele, L. Bergeron, and R.J. Sims III Targeting MYC dependence in cancer by inhibiting BET bromodomains Proc. Natl. Acad. Sci. USA 108 2011 16669 16674
65. N. Meyer, and L.Z. Penn Reflecting on 25 years with MYC Nat. Rev. Cancer 8 2008 976 990
66. S. Minucci, and P.G. Pelicci Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat. Rev. Cancer 6 2006 38 51 (Pubitemid 43054973)
67. K. Moran-Crusio, L. Reavie, A. Shih, O. Abdel-Wahab, D. Ndiaye-Lobry, C. Lobry, M.E. Figueroa, A. Vasanthakumar, J. Patel, and X. Zhao Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation Cancer Cell 20 2011 11 24
68. R.D. Morin, N.A. Johnson, T.M. Severson, A.J. Mungall, J. An, R. Goya, J.E. Paul, M. Boyle, B.W. Woolcock, and F. Kuchenbauer Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin Nat. Genet. 42 2010 181 185
69. R.D. Morin, M. Mendez-Lago, A.J. Mungall, R. Goya, K.L. Mungall, R.D. Corbett, N.A. Johnson, T.M. Severson, R. Chiu, and M. Field Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma Nature 476 2011 298 303
70. N. Mosammaparast, and Y. Shi Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases Annu. Rev. Biochem. 79 2010 155 179
71. E. Nicodeme, K.L. Jeffrey, U. Schaefer, S. Beinke, S. Dewell, C.W. Chung, R. Chandwani, I. Marazzi, P. Wilson, and H. Coste Suppression of inflammation by a synthetic histone mimic Nature 468 2010 1119 1123
72. G. Nikoloski, S.M. Langemeijer, R.P. Kuiper, R. Knops, M. Massop, E.R. Tönnissen, A. van der Heijden, T.N. Scheele, P. Vandenberghe, and T. de Witte Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes Nat. Genet. 42 2010 665 667
73. P. Ntziachristos, A. Tsirigos, P. Van Vlierberghe, J. Nedjic, T. Trimarchi, M.S. Flaherty, D. Ferres-Marco, V. da Ros, Z. Tang, and J. Siegle Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia Nat. Med. 18 2012 298 301
74. J.E. Ohm, K.M. McGarvey, X. Yu, L. Cheng, K.E. Schuebel, L. Cope, H.P. Mohammad, W. Chen, V.C. Daniel, and W. Yu A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing Nat. Genet. 39 2007 237 242 (Pubitemid 46184356)
75. M. Okano, D.W. Bell, D.A. Haber, and E. Li DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development Cell 99 1999 247 257 (Pubitemid 29519904)
76. E.A. Olsen, Y.H. Kim, T.M. Kuzel, T.R. Pacheco, F.M. Foss, S. Parker, S.R. Frankel, C. Chen, J.L. Ricker, J.M. Arduino, and M. Duvic Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma J. Clin. Oncol. 25 2007 3109 3115 (Pubitemid 47218059)
77. P.J. Park ChIP-seq: advantages and challenges of a maturing technology Nat. Rev. Genet. 10 2009 669 680
78. L. Pasqualucci, D. Dominguez-Sola, A. Chiarenza, G. Fabbri, A. Grunn, V. Trifonov, L.H. Kasper, S. Lerach, H. Tang, and J. Ma Inactivating mutations of acetyltransferase genes in B-cell lymphoma Nature 471 2011 189 195
79. J.P. Patel, M. Gönen, M.E. Figueroa, H. Fernandez, Z. Sun, J. Racevskis, P. Van Vlierberghe, I. Dolgalev, S. Thomas, and O. Aminova Prognostic relevance of integrated genetic profiling in acute myeloid leukemia N. Engl. J. Med. 366 2012 1079 1089
80. R.L. Piekarz, R. Frye, M. Turner, J.J. Wright, S.L. Allen, M.H. Kirschbaum, J. Zain, H.M. Prince, J.P. Leonard, and L.J. Geskin Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J. Clin. Oncol. 27 2009 5410 5417
81. C. Quivoron, L. Couronné, V. Della Valle, C.K. Lopez, I. Plo, O. Wagner-Ballon, M. Do Cruzeiro, F. Delhommeau, B. Arnulf, and M.H. Stern TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis Cancer Cell 20 2011 25 38
82. O.J. Rando, and H.Y. Chang Genome-wide views of chromatin structure Annu. Rev. Biochem. 78 2009 245 271
83. K.D. Robertson DNA methylation and human disease Nat. Rev. Genet. 6 2005 597 610 (Pubitemid 41044297)
84. L. Rui, N.C. Emre, M.J. Kruhlak, H.J. Chung, C. Steidl, G. Slack, G.W. Wright, G. Lenz, V.N. Ngo, and A.L. Shaffer Cooperative epigenetic modulation by cancer amplicon genes Cancer Cell 18 2010 590 605
85. A.J. Ruthenburg, H. Li, T.A. Milne, S. Dewell, R.K. McGinty, M. Yuen, B. Ueberheide, Y. Dou, T.W. Muir, D.J. Patel, and C.D. Allis Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions Cell 145 2011 692 706
86. T. Schenk, W.C. Chen, S. Göllner, L. Howell, L. Jin, K. Hebestreit, H.U. Klein, A.C. Popescu, A. Burnett, and K. Mills Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia Nat. Med. 18 2012 605 611
87. J. Schwartzentruber, A. Korshunov, X.Y. Liu, D.T. Jones, E. Pfaff, K. Jacob, D. Sturm, A.M. Fontebasso, D.A. Quang, and M. Tönjes Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma Nature 482 2012 226 231
88. E. Segal, and J. Widom From DNA sequence to transcriptional behaviour: a quantitative approach Nat. Rev. Genet. 10 2009 443 456
89. D.B. Seligson, S. Horvath, T. Shi, H. Yu, S. Tze, M. Grunstein, and S.K. Kurdistani Global histone modification patterns predict risk of prostate cancer recurrence Nature 435 2005 1262 1266 (Pubitemid 40943093)
90. C.J. Sneeringer, M.P. Scott, K.W. Kuntz, S.K. Knutson, R.M. Pollock, V.M. Richon, and R.A. Copeland Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas Proc. Natl. Acad. Sci. USA 107 2010 20980 20985
91. M.R. Stratton, P.J. Campbell, and P.A. Futreal The cancer genome Nature 458 2009 719 724
92. M. Stucki, J.A. Clapperton, D. Mohammad, M.B. Yaffe, S.J. Smerdon, and S.P. Jackson MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks Cell 123 2005 1213 1226 (Pubitemid 41821780)
93. H.G. Stunnenberg, and M. Vermeulen Towards cracking the epigenetic code using a combination of high-throughput epigenomics and quantitative mass spectrometry-based proteomics Bioessays 33 2011 547 551
94. M. Tahiliani, K.P. Koh, Y. Shen, W.A. Pastor, H. Bandukwala, Y. Brudno, S. Agarwal, L.M. Iyer, D.R. Liu, L. Aravind, and A. Rao Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 Science 324 2009 930 935
95. M. Tan, H. Luo, S. Lee, F. Jin, J.S. Yang, E. Montellier, T. Buchou, Z. Cheng, S. Rousseaux, and N. Rajagopal Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification Cell 146 2011 1016 1028
96. S.D. Taverna, H. Li, A.J. Ruthenburg, C.D. Allis, and D.J. Patel How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers Nat. Struct. Mol. Biol. 14 2007 1025 1040 (Pubitemid 350060344)
97. H.C. Tsai, H. Li, L. Van Neste, Y. Cai, C. Robert, F.V. Rassool, J.J. Shin, K.M. Harbom, R. Beaty, and E. Pappou Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells Cancer Cell 21 2012 430 446
98. G. van Haaften, G.L. Dalgliesh, H. Davies, L. Chen, G. Bignell, C. Greenman, S. Edkins, C. Hardy, S. O'Meara, and J. Teague Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer Nat. Genet. 41 2009 521 523
99. I. Varela, P. Tarpey, K. Raine, D. Huang, C.K. Ong, P. Stephens, H. Davies, D. Jones, M.L. Lin, and J. Teague Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma Nature 469 2011 539 542
100. M. Vermeulen, H.C. Eberl, F. Matarese, H. Marks, S. Denissov, F. Butter, K.K. Lee, J.V. Olsen, A.A. Hyman, H.G. Stunnenberg, and M. Mann Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers Cell 142 2010 967 980
101. I. Versteege, N. Sévenet, J. Lange, M.F. Rousseau-Merck, P. Ambros, R. Handgretinger, A. Aurias, and O. Delattre Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer Nature 394 1998 203 206 (Pubitemid 28325977)
102. K.C. Wang, and H.Y. Chang Molecular mechanisms of long noncoding RNAs Mol. Cell 43 2011 904 914
103. J. Wang, H. Iwasaki, A. Krivtsov, P.G. Febbo, A.R. Thorner, P. Ernst, E. Anastasiadou, J.L. Kutok, S.C. Kogan, and S.S. Zinkel Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease EMBO J. 24 2005 368 381 (Pubitemid 40216141)
104. G.G. Wang, C.D. Allis, and P. Chi Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling Trends Mol. Med. 13 2007 373 380 (Pubitemid 47385382)
105. Z. Wang, C. Zang, J.A. Rosenfeld, D.E. Schones, A. Barski, S. Cuddapah, K. Cui, T.Y. Roh, W. Peng, M.Q. Zhang, and K. Zhao Combinatorial patterns of histone acetylations and methylations in the human genome Nat. Genet. 40 2008 897 903 (Pubitemid 351913645)
106. G.G. Wang, J. Song, Z. Wang, H.L. Dormann, F. Casadio, H. Li, J.-L. Luo, D.J. Patel, and C.D. Allis Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger Nature 459 2009 847 851
107. K. Wang, J. Kan, S.T. Yuen, S.T. Shi, K.M. Chu, S. Law, T.L. Chan, Z. Kan, A.S. Chan, and W.Y. Tsui Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer Nat. Genet. 43 2011 1219 1223
108. I.B. Weinstein Cancer. Addiction to oncogenes - the Achilles heal of cancer Science 297 2002 63 64 (Pubitemid 34743088)
109. B.G. Wilson, and C.W. Roberts SWI/SNF nucleosome remodellers and cancer Nat. Rev. Cancer 11 2011 481 492
110. H. Wu, and Y. Zhang Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation Genes Dev. 25 2011 2436 2452
111. G. Wu, A. Broniscer, T.A. McEachron, C. Lu, B.S. Paugh, J. Becksfort, C. Qu, L. Ding, R. Huether, M. Parker St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas Nat. Genet. 44 2012 251 253
112. B. Xhemalce, M.A. Dawson, and A.J. Bannister Histone Modifications Encyclopedia of Molecular Cell Biology and Molecular Medicine 2011 Wiley-VCH Verlag Weinheim
113. W. Xu, H. Yang, Y. Liu, Y. Yang, P. Wang, S.H. Kim, S. Ito, C. Yang, P. Wang, and M.T. Xiao Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Cancer Cell 19 2011 17 30
114. X. Yang, W. Cao, L. Zhang, W. Zhang, X. Zhang, and H. Lin Targeting 14-3-3zeta in cancer therapy Cancer Gene Ther. 19 2012 153 159
115. J. Zhang, L. Ding, L. Holmfeldt, G. Wu, S.L. Heatley, D. Payne-Turner, J. Easton, X. Chen, J. Wang, and M. Rusch The genetic basis of early T-cell precursor acute lymphoblastic leukaemia Nature 481 2012 157 163
116. J. Zuber, J. Shi, E. Wang, A.R. Rappaport, H. Herrmann, E.A. Sison, D. Magoon, J. Qi, K. Blatt, and M. Wunderlich RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 478 2011 524 528